Compare Baker Hughes Co (BKR) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baker Hughes Co vs Crispr Therapeutics AG — how do they compare? Baker Hughes Co trades at $64.74 (market cap $64.34B), while Crispr Therapeutics AG trades at $54.08 (market cap $5.23B). The key difference: Baker Hughes Co is far larger — about 12.3× Crispr Therapeutics AG's market cap, and Baker Hughes Co pays a 1.42% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| BKR | CRSP | |
|---|---|---|
Market Cap | $64.34B | $5.23B |
Sector | Energy | Health |
52-Week High | $69.67 | $76.78 |
52-Week Low | $42.51 | $44.34 |
Enterprise Value | $64.86B | $3.65B |
Dividend Yield | 1.42% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
